<DOC>
	<DOCNO>NCT01700608</DOCNO>
	<brief_summary>Plerixafor new CXCR4 inhibitor able improve peripheral blood stem cell ( PBSC ) mobilization combine granulocyte-colony-stimulating factor ( G-CSF ) . The 'on demand ' use plerixafor hematopoietic recovery chemotherapy + G-CSF may efficient cost-effective , time administration criterion patient selection still investigation . We collect data lymphoma myeloma patient treat plerixafor hematopoietic recovery chemotherapy + G-CSF . The decision add plerixafor base PB CD34+ cell time hematopoietic recovery chemotherapy patient first subsequent attempt , accord attend physician choice . The primary endpoint assessment rate patient able collect &gt; =2 x 10^6 CD34+/kg .</brief_summary>
	<brief_title>Prospective Observational Study Plerixafor After Chemotherapy</brief_title>
	<detailed_description>Plerixafor new CXCR4 inhibitor able improve peripheral blood stem cell ( PBSC ) mobilization combine granulocyte-colony-stimulating factor ( G-CSF ) . The 'on demand ' use plerixafor hematopoietic recovery chemotherapy + G-CSF may efficient cost-effective , time administration criterion patient selection still investigation . We collect data lymphoma myeloma patient treat plerixafor hematopoietic recovery chemotherapy + G-CSF . The decision add plerixafor base PB CD34+ cell time hematopoietic recovery chemotherapy patient first subsequent attempt , accord attend physician choice . The primary endpoint assessment rate patient able collect &gt; =2 x 10^6 CD34+/kg . Secondary endpoint assessment rate patient collect &gt; 4 x 10^6 CD34+/kg median number apheresis reach target .</detailed_description>
	<mesh_term>JM 3100</mesh_term>
	<criteria>lymphoma myeloma patient treat plerixafor hematopoietic recovery chemotherapy GCSF patient treat GCSF plerixafor without chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>